-

Octapharma Injects Efficiency Into Its Supply Chain With Kinaxis

Global healthcare company will streamline operations and achieve end-to-end supply chain orchestration

OTTAWA, Ontario--(BUSINESS WIRE)--Octapharma, the largest privately owned company dedicated to the research and development of life-saving or life-altering therapies, has selected Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, to connect data systems and modernize its supply chain.

Octapharma, headquartered in Lachen, Switzerland, focuses on three therapeutic areas: hematology, immunotherapy and critical care. Its products are available in 118 countries and reach hundreds of thousands of patients every year, having a direct impact on the quality of life of those patients and underscoring the importance of having a resilient and effective supply chain.

“Kinaxis is known within the life sciences and pharmaceutical community, and they understand the unique complexities that come along with managing our supply chains,” said Fabien Huyghe, strategic planning director at Octapharma. “We trust that their partnership will be hugely beneficial to our business.”

With the Kinaxis Maestro platform, Octapharma will orchestrate its supply chain, enabling the agility needed to make fast and accurate decisions, with positive impacts to the company’s bottom line.

“Being able to provide patients around the world with life-saving medicine is a huge honor and responsibility that we take seriously,” said Fabienne Cetre, executive vice president of EMEA at Kinaxis. “We are excited to partner with Octapharma on their supply chain journey to help them innovate and deliver more medicine to the people that need it the most.”

With the addition of Octapharma to its growing customer base, Kinaxis continues to cement its footprint within the life sciences industry, which provides the brand-name and generic medicines that countless patients rely on. Managing supply chain complexities in biotechnology, cell and gene therapy, medical devices, over-the-counter medicines and more, Kinaxis customers include some of the world's top pharma companies, such as Dr. Reddy's, Jamieson Wellness, Merck, Novartis, Siemens Healthineers and Servier.

To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Kinaxis Inc.

TSX:KXS


Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Social Media Profiles
More News From Kinaxis Inc.

Kinaxis Introduces Maestro Agent Studio, Unlocking Next Level Decision Making Through Composable AI Agents

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX: KXS), the leader in supply chain orchestration, today announced Maestro Agent Studio, making the next phase of its AI agent strategy available to customers following the launch of prebuilt Maestro Agents. Maestro Agent Studio gives supply chain teams a no-code way to compose AI agents grounded in their real operating context, using the same data, workflows, and tools planners already rely on, so agents drive real-world outcomes. Built into t...

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 2026

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial resu...

Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable un...
Back to Newsroom